Coeptis Therapeutics, Inc. (COEP) has a negative trailing P/E of -6.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -16.15%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2004 | 0.1 | 0.00 | -1.40 | 0.00 | - |
| 2005 | -1.1 | 0.01 | -0.67 | 0.00 | - |
| 2018 | -15,090.4 | 0.00 | 5,953.83 | 0.00 | - |
| 2019 | -955,545.0 | 9,702.46 | 136,036.67 | 0.00 | - |
| 2020 | -455.0 | 0.00 | -809.96 | 135,427.19 | - |
| 2021 | -15.2 | -0.01 | 86.96 | 2,725.33 | - |
| 2022 | -11.7 | 0.15 | 98.30 | 0.00 | - |
| 2023 | -18.9 | 0.27 | 93.38 | 0.00 | - |
| 2024 | -1.0 | 0.00 | 3.32 | 0.00 | - |
| 2025 | -5.1 | 0.10 | 3.50 | 44.27 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2004 | $1,421.16 | $0.00 | $2.65M | - |
| 2005 | $-184.81 | $0.00 | $-344K | - |
| 2018 | $-0.01 | $0.00 | $-7.07K | - |
| 2019 | $0.00 | $0.00 | $-2.23K | - |
| 2020 | $-0.45 | $30.76K | $-9.16M | -29765% |
| 2021 | $-13.16 | $75K | $-13.45M | -17932% |
| 2022 | $-2.87 | $0.00 | $-37.57M | - |
| 2023 | $-0.83 | $0.00 | $-21.27M | - |
| 2024 | $-5.10 | $0.00 | $-9.81M | - |
| 2025 | $-2.81 | $1.36M | $-11.92M | -874.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.40 | $-3.40 – $-3.40 | $1.02M | $1.02M – $1.02M | 1 |
| 2027 | $-3.60 | $-3.60 – $-3.60 | $766.71K | $766.71K – $766.71K | 1 |
